Madrigal Pharmaceuticals Inc (MDGL)

[roadkilll]

Madrigal at 52 week lows because it is off the radar
Phase 3 NAFLD results coming soon and I'll be looking for a clean safety profile and indications nonintrusive biomarkers can be used to follow therapy and to diagnose NASH (not NAFLD).

Looking back at Phase 2 results confirmed with biopsy in NASH phase 2 trial
Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints

Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved a two point reduction in NAS (NAFLD activity score) on biopsy --

-- Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved resolution of NASH on biopsy --

Current phase 3 trial will dose 52 weeks not the 36 weeks in the phase 2 trial. The current phase 3 trial will also be based on higher doses that were much more effective at reducing liver fat by >50%. 50% liver fat reduction is considered ideal to see liver improvement.

Two phase 3 trials with focus on NASH. NAFLD arm will likely be difficult to show improvement over placebo in a short term trial. The NAFLD news coming soon is an expected buying op for me as the headliner will be about treating NAFLD for 52 weeks probably being the headline and an op for Wall Street to attack the price so that they can collect cheaper shares before NASH results next year.